CoChat

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). In the case of drug-related grade ≥3 or selected prolonged grade 2 adverse events (AEs), the dose can be reduced by 10 mg decrements to a minimum of 20 mg. Here, we evaluate the influence of afatinib dose reduction on AEs, pharmacokinetics and progression-free survival (PFS) in the phase III LUX-Lung 3 and 6 (LL3/6) trials. PATIENTS AND METHODS: Treatment-naïve patients with advanced EGFR mutation-positive NSCLC in LL3 (global) and LL6 (China, Thailand, South Korea) were randomized to afatinib or chemotherapy. All afatinib-treated patients (LL3, n = 229; LL6, n = 239) were included in the post hoc analyses. Incidence and severity of common AEs before and after afatinib dose reduction were assessed. Afatinib plasma concentrations were compared in patients who reduced to 30 mg versus those remaining at 40 mg. PFS was compared between patients who dose reduced within the first 6 months of treatment and those who did not. RESULTS: Dose reductions occurred in 53.3% (122/229) and 28.0% (67/239) of patients in LL3 and LL6, respectively; most (86.1% and 82.1%) within the first 6 months of treatment. Dose reduction led to decreases in the incidence of drug-related AEs, and was more likely in patients with higher afatinib plasma concentrations. On day 43, patients who dose reduced to 30 mg (n = 59) had geometric mean afatinib plasma concentrations of 23.3 ng/ml, versus 22.8 ng/ml in patients who remained on 40 mg (n = 284). The median PFS was similar in patients who dose reduced during the first 6 months versus those who did not {LL3: 11.3 versus 11.0 months [hazard ratio (HR) 1.25]; LL6: 12.3 versus 11.0 months (HR 1.00)}. CONCLUSIONS: Tolerability-guided dose adjustment is an effective measure to reduce afatinib-related AEs without affecting therapeutic efficacy. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov identifiers: NCT00949650 and NCT0112393.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw322

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Yang, 2013, Epidermal growth factor receptor (EGFR)-mediated adverse events in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) treated with afatinib, Eur J Cancer, 49, 895

Cited by

See all 194

Metadata

Authors
Yang, J. C.-H., Sequist, L. V., Zhou, C., Schuler, M., Geater, S. L., Mok, T., Hu, C.-P., Yamamoto, N., Feng, J., O'Byrne, K., Lu, S., Hirsh, V., Huang, Y., Sebastian, M., Okamoto, I., Dickgreber, N., Shah, R., Märten, A., Massey, D., Wind, S., & Wu, Y.-L.
Affiliations
  • National Taiwan University Hospital (TW)
  • Harvard University (US)
  • Tongji University (CN)
  • Prince of Songkla University (TH)
  • Chinese University of Hong Kong (HK)
  • Xiangya Hospital Central South University (CN)
  • Wakayama Medical University (JP)
  • Jiangsu Cancer Hospital (CN)
  • Queensland University of Technology (AU)
  • McGill University (CA)
  • Kunming Medical University (CN)
  • Goethe University Frankfurt (DE)
  • Kyushu University (JP)
  • Klinikum Rheine (DE)
  • Maidstone Hospital (GB)
  • Boehringer Ingelheim (Germany) (DE)
  • Guangdong General Hospital (CN)
Corresponding author
Wu, Y.-L.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2016-11
Volume
27
Issue
11
Pages
2103-2110
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2512922897
Cited by
194
References
24
Citations by year
2026: 10 · 2025: 12 · 2024: 9 · 2023: 13 · 2022: 15 · 2021: 34 · 2020: 21 · 2019: 34 · 2018: 24 · 2017: 21 · 2016: 1
FWCI
23.86
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
afatinib, EGFR-mutant non-small cell lung cancer, lung adenocarcinoma, dose reduction, dose adjustment, adverse events, pharmacokinetics, plasma drug concentration, progression-free survival, first-line therapy, tyrosine kinase inhibitors, tolerability, efficacy, Chinese patients, Thai patients, South Korean patients
MeSH terms
Adenocarcinoma of Lung, Afatinib, Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, China, Dose-Response Relationship, Drug, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Quinazolines, Disease-Free Survival, Protein Kinase Inhibitors, Republic of Korea, Drug-Related Side Effects and Adverse Reactions, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. https://app.cochat.ai/papers/10.1093/annonc/mdw322
The paper
Yang, J. C.-H., Sequist, L. V., Zhou, C., Schuler, M., Geater, S. L., Mok, T., Hu, C.-P., Yamamoto, N., Feng, J., O'Byrne, K., Lu, S., Hirsh, V., Huang, Y., Sebastian, M., Okamoto, I., Dickgreber, N., Shah, R., Märten, A., Massey, D., . . . Wu, Y.-L. (2016). Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Annals of Oncology. https://doi.org/10.1093/annonc/mdw322

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.